

More information on the trials listed below is available at PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at www.cancer.gov/clinicaltrials. A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.

Bladder

Phase III Randomized Study of Intravesical Gemcitabine Hydrochloride Immediately After Transurethral Resection of the Bladder Tumor in Patients With Newly Diagnosed or Recurrent Superficial Transitional Cell Bladder Cancer
SWOG-S0337, NCT00445601

Phase II Randomized Study of Induction Paclitaxel, Cisplatin, and Radiotherapy Versus Fluorouracil, Cisplatin, and Radiotherapy Followed By Consolidation Chemoradiotherapy or Radical Cystectomy and Adjuvant Gemcitabine, Paclitaxel, and Cisplatin in Patients With Operable Stage II or III Bladder Cancer
RTOG-0233, NCT00055601, ECOG-R0233

Phase II Randomized Study of Neoadjuvant Gemstein in Patients Undergoing Surgical Resection for Bladder Cancer
WCCC-CO-04307, WCCC-H-2005-0026, WCCC-UWI03-1-01, NCT00118040

Phase I Study of Neoadjuvant Intravesical Recombinant Fowlpox-TRICOM Vaccine and/or Recombinant Fowlpox-Sargramostim Vaccine in Patients With Bladder Carcinoma Undergoing Cystectomy
CINJ-3909, NCT00072137, NCI-5585

Study to Investigate the Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients With Bladder Cancer Undergoing Radical or Total Cystectomy
12002, NCT00306150

Prostate

Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low-Risk, Localized Prostate Cancer
G050103, NCT00295802

Phase III Randomized Study of Radical Prostatectomy With Versus Without Neoadjuvant Chemo-

hormonal Therapy Comprising Docetaxel and Androgen-Deprivation Therapy With Leuprolide Acetate or Goserelin in Patients With High-Risk, Clinically Localized Prostate Cancer
CALGB-90203, NCT00430183

Phase II Study of Adjuvant Chemoradiotherapy Comprising Docetaxel and External-Beam Radiotherapy Followed by Docetaxel and Prednisone in Patients With Prostate Cancer Who Fail to Achieve a Prostate-Specific Antigen Nadir of Zero After Radical Prostatectomy
UTHSC-045-0015-377, NCT00348816

Phase II Randomized Study of Neoadjuvant Lycopene Supplementation in Patients Undergoing Radical Prostatectomy for Prostate Cancer
MDA-04-3-01, NCT00450749, MDA04-3-01

Phase III Randomized Study of Hormonal Therapy and Docetaxel Versus Hormonal Therapy Alone in Patients With Metastatic Prostate Adenocarcinoma
FRE-FNCLCC-GETUG-15/0403, NCT00104715

Phase II Randomized Pilot Study of Samarium Sm 153 Lexidronam Pentasodium With Versus Without Recombinant Fowlpox-TRICOM Vaccine, Recombinant Vaccinia-TRICOM Vaccine, and Sargramostim (GM-CSF) in Patients With Androgen-Insensitive, Prostate Cancer Metastatic to the Bone
NCI-07-C-0106, NCT00450619, 07-C-0106

Phase III Randomized Study of Interstitial Brachytherapy With or Without External Beam Radiotherapy in Patients With Intermediate-Risk Prostate Cancer
RTOG-0232, CTSU, NCT00063882

Renal

Phase II Study of Sunitinib Malate in Patients With Progressive Metastatic Transitional Cell Carcinoma of the Urothelium
MSKCC-06081, NCT00397488

Phase II Study of Sorafenib in Patients With Progressive Regional or Metastatic Carcinoma of the Urothelium
ECOG-E1804, NCT00112905

Randomized Study of Docetaxel ± ZD6474 in Metastatic TCC
06-116, NCT00378794

Phase II Study of VEGF Trap in Patients With Recurrent, Locoregionally Advanced, or Metastatic Transitional Cell Carcinoma of the Urothelium
CCC-PHII-76, NCT00407485

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

UMCC 2005.145, NCT00393796

The following trials are currently being conducted at Moffitt Cancer Center. For additional information about these trials, please contact Tamela M. Kovalchek at (813) 745-3982 or e-mail: tamela.kovalchek@moffitt.org.

Bladder

Phase II of Study Neoadjuvant Cisplatin, Gemcitabine, and Bevacizumab Followed by Radical Cystectomy for Patients With Muscle-Invasive, Resectable, Nonmetastatic Transitional Cell Carcinoma (TCC) of the Bladder

MCC 15211; trial to open soon.

Prostate

Prospective Study of Health-Related Quality of Life and Oncological Outcomes After Laparoscopic Radical Prostatectomy

MCC 14499

A Multi-Center, Open-Label, Randomized Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy Eligard (Leuprolide Acetate) in Combination With Taxotere (Docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy

MCC 14732

A Randomized Multicenter Phase II Trial of Patupilone Plus Prednisone Versus Taxotere and Prednisone in Patients With Metastatic Hormone Refractory Prostate Cancer

MCC 14899

Effectiveness Evaluation of the Anastomosis Device in Facilitating the Vesico-Urethral Anastomosis Following a Radical Prostatectomy

MCC trial # pending; trial to open soon.

Renal

A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib Versus Sorafenib Versus Placebo in Patients With Resected Renal Cell Carcinoma

MCC 14893

A Randomized, Double-Blind Study With Trovax Added to First-Line Standard of Care Therapy Prolongs the Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma

MCC 14987; trial to open soon.

A Phase II Randomized, Double-Blinded Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo as First-Line Therapy for Patients With Metastatic Clear Cell Carcinoma of the Kidney

MCC 15205; trial to open soon.

A Multi-Center, Phase III Study of Pazopanib and Lapatinib in Combination to Pazopanib Monotherapy in Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

MCC trial # pending; trial to open soon.